Incidence of Blepharoptosis Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections
- PMID: 38461944
- PMCID: PMC11934865
- DOI: 10.1016/j.ajo.2024.02.031
Incidence of Blepharoptosis Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections
Abstract
Purpose: To determine the incidence of blepharoptosis after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections and compare the rates of blepharoptosis between patients injected with an eyelid speculum and those injected without a speculum.
Design: Retrospective cohort study.
Methods: International Classification of Diseases, Tenth Revision (ICD-10), codes were used to identify patients with exudative age-related macular degeneration (AMD) and those who developed ptosis after intravitreal injections. Patients with nonexudative AMD who did not receive intravitreal injections served as controls. The outcomes were the incidence of ptosis in the injection group compared to the noninjection group and incidence of ptosis in patients whose injections were performed with an eyelid speculum as compared to those whose injections were performed without a speculum.
Results: We recruited 1100 exudative AMD patients who received at least 1 intravitreal anti-VEGF injection and 2258 nonexudative AMD patients who had not received an injection. In the injection group, 18 of 1100 patients (1.6%) developed ptosis, compared with 52 of 2258 patients (2.3%) in the noninjection group (P = .25). Within the injection group, ptosis was mostly bilateral, diagnosed on average 22.4 months after the initial injection, and after more than a 1-year injection-free period. Eleven of 537 patients (2.0%) injected without a speculum developed ptosis, compared with 8 of 444 patients (1.8%) injected with a speculum (P = .82).
Conclusions: No statistically significant differences in incidence rates of ptosis were observed. In this analysis, neither intravitreal anti-VEGF injections nor speculum use during injections appears to increase the risk of ptosis.
Copyright © 2024. Published by Elsevier Inc.
Figures


Similar articles
-
Risk of ptosis following eyelid speculum assisted intravitreal anti-VEGF injections.Graefes Arch Clin Exp Ophthalmol. 2025 Jun;263(6):1711-1717. doi: 10.1007/s00417-025-06763-3. Epub 2025 Feb 13. Graefes Arch Clin Exp Ophthalmol. 2025. PMID: 39945841 Free PMC article.
-
Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.Ophthalmology. 2015 Aug;122(8):1569-72. doi: 10.1016/j.ophtha.2015.04.028. Epub 2015 May 30. Ophthalmology. 2015. PMID: 26038338
-
Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.Ophthalmology. 2018 Jan;125(1):66-74. doi: 10.1016/j.ophtha.2017.07.005. Epub 2017 Aug 8. Ophthalmology. 2018. PMID: 28801117
-
Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.Cochrane Database Syst Rev. 2020 May 5;5(5):CD012208. doi: 10.1002/14651858.CD012208.pub2. Cochrane Database Syst Rev. 2020. PMID: 32374423 Free PMC article.
-
Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.Drugs Aging. 2015 Oct;32(10):797-807. doi: 10.1007/s40266-015-0300-y. Drugs Aging. 2015. PMID: 26442858 Free PMC article. Review.
Cited by
-
Risk of ptosis following eyelid speculum assisted intravitreal anti-VEGF injections.Graefes Arch Clin Exp Ophthalmol. 2025 Jun;263(6):1711-1717. doi: 10.1007/s00417-025-06763-3. Epub 2025 Feb 13. Graefes Arch Clin Exp Ophthalmol. 2025. PMID: 39945841 Free PMC article.
References
-
- Campa C, Alivernini G, Bolletta E, Battaglia Parodi M, & Perri P. Anti-VEGF Therapy for Retinal Vein Occlusions. Current Drug Targets 2016;17(3):328–336. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources